Galanin is a peptide widely distributed throughout vertebrate central and peripheral nervous systems. Although its precise physiologic role is unknown, it can stimulate the pituitary secretion of prolactin and growth hormone. We examined the control of rat galanin (rGal) gene expression in the anterior pituitary using RNA blot and in situ hybridization analyses and using specific RIA. Pituitaries of normal male and ovariectomized female rats contained little detectable rGal mRNA. Treatment of these animals with 17fi-estradiol increased pituitary rGal mRNA up to 4000-fold.
17fi-estradiol increased pituitary rGal mRNA up to 4000-fold.
These increases depended on time and dose of estrogen administration and correlated with up to 50-fold increases in pituitary galanin-like immunoreactivity. Galanin-like immunoreactivity was detectable in the plasma of estrogen-treated animals. Pituitary levels of rGal mRNA in female rats varied >30-fold during the estrous cycle, with a peak on estrus and a nadir on diestrus. Estrogen-induced rGal gene expression was also observed in transplantable MtTW1s prolactin-and growth hormone-containing tumors but not in neuronal tissues expressing this gene. These data demonstrate that rGal is a secreted product of rat anterior pituitary cells, where its gene expression is strongly affected by physiologic levels of circulating estrogen.
Galanin is a 29-amino acid peptide, initially isolated from porcine intestine, that has little similarity to other known peptides (1) . Galanin-like immunoreactivity (Gal-IR) is widely distributed in central and peripheral neurons of several mammalian species including humans, nonhuman primates, dogs, cats, cows, and various rodents (2) . In addition, Gal-IR has been detected in bovine and porcine adrenal medulla (2, 3) . Its intracellular localization suggests that galanin may function as a neurotransmitter. Moreover, a 53-to 55-kDa peptide has been isolated from the cell membrane fraction of rat brain and a hamster pancreatic beta cell tumor that selectively binds radiolabeled galanin with high affinity, consistent with a role as a galanin receptor protein (4, 5) .
Although the precise physiologic role of galanin has not been established, the peptide has been shown to have several pharmacologic properties in whole animal and isolated tissue preparations. Direct injection of porcine galanin (pGal) into the third ventricle of rats increases plasma concentrations of growth hormone (GH) and prolactin and decreases dopamine concentrations in the median eminence (6) (7) (8) (9) . Intravenous pGal injection in humans stimulates GH release and augments the GH release induced by exogenous GH-releasing hormone (10, 11) . pGal has little stimulatory effect on the release of these hormones in isolated pituitary preparations (6, (12) (13) (14) , and there is evidence that its effects are exerted indirectly via the release of dopamine (for prolactin) and somatostatin (for GH) (8, 11, 15) . Intracerebroventricular pGal increases luteinizing hormone release in ovariectomized rats treated with exogenous estrogen and progesterone (16) . Intravenous pGal infusion in dogs and humans leads to glucose tolerance or frank hyperglycemia (2) . The effect in dogs is associated with an elevation in plasma glucagon and depression in plasma insulin, somatostatin, and pancreatic polypeptide (17) (18) (19) (20) . pGal administration also inhibits insulin release from cultured rat insulinoma cells, an effect mediated by its activation of the ATP-sensitive potassium channel (21) . pGal modulates smooth muscle contractility within the gastrointestinal and genitourinary tracts, with the net effect (stimulatory or inhibitory) dependent upon the species and muscle preparation studied (2) .
pGal is encoded as part of a 123-amino acid precursor peptide (prepro-pGal) that includes a signal sequence, galanin, and a 59-amino acid galanin mRNA-associated peptide (22) . We have recently isolated and characterized cDNA clones encoding rat galanin (rGal) (23) . The structure of these cDNAs indicates that rGal is encoded as part of a 124-amino acid precursor (prepro-rGal) that shares several regions of similarity with prepro-pGal, including 90% identity of the galanin portion and 78% identity of a 35-amino acid region of the galanin mRNA-associated peptide (23) .
RNA blot analysis demonstrated that rGal mRNA is most abundant in hypothalamus (23) 6 wk after implantation). Animals were gonadectomized and/or injected s.c. daily with steroid hormones in sesame oil except as indicated; control animals received oil alone. Gonadectomy was done 4 wk before the start of hormone administration. Except as noted, animals were sacrificed by decapitation after 7-day treatment (24 hr after last dose). Pituitaries and tumors were dissected, quick-frozen, and stored at -70'C for later processing.
Nucleic Acid Preparation and Hybridization. Total RNA from rat tissues was isolated using standard methods (23, 24) . RNA was separated by formaldehyde/agarose gel electrophoresis, transferred to Nytran membranes (Schleicher & Schuell), and hybridized with complementary RNA (cRNA) probes at 650C as described (23) . Radiolabeled cRNA probes were prepared from an rGal-specific cDNA (rG-2 in ref. 23) subcloned into pGEM3-blue (Promega Biotec, Madison, WI) and transcribed with T7 RNA polymerase as described (23, 25) . Concentrations of rGal mRNA were determined by densitometric scanning of autoradiograms of RNA blots (26) . These values were standardized to the total RNA loaded on the gel by densitometric scanning of the ribosomal RNA bands of the ethidium bromide-stained gel (before blotting).
In Situ Hybridization. Whole pituitaries were isolated as described above and fixed in 4% (wt/vol) paraformaldehyde.
Cryostat sections (10 mm thick) were affixed to glass slides, hybridized to 35S-labeled rGal cRNA (23), immersed in Kodak NTB-2 photographic emulsion, exposed for 8 days, developed, and counterstained with methyl green as described (27) . RIA. Tissues for RIA were extracted in 2 M acetic acid at 100°C for 20 min as described (28) . Assays were done by standard methods with rabbit antisera directed against pGal conjugated to keyhole limpet hemocyanin (28) . The RIA has an ED50 of 250 pg and a sensitivity of 25 pg. Binding inhibition curves of rat brain extracts parallel those of the pGal standard. There is no measurable cross-reactivity with other known peptides (28) .
RESULTS
RNA blot hybridization analysis revealed that pituitaries from randomly cycling females contained -20-fold more rGal mRNA than their male counterparts. Ovariectomy reduced rGal pituitary mRNA levels to those seen in male rats, whereas castration of males had no significant effect (Fig.  1B) . Sex-dependent differences in rGal mRNA concentrations were not seen in several other tissues examinedincluding hypothalamus, cerebral cortex, septum, amygdala, brainstem, stomach, duodenum, and adrenal (data not shown).
Treatment of ovariectomized female rats with pharmacological doses (10 ,g per 100 g of body weight) of 17f3-estradiol daily for 7 days stimulated pituitary rGal mRNA levels >2800-fold (Figs. 1 A and B) . This treatment produced <2-fold changes in the concentrations of rGal mRNA in the hypothalamus and had no detectable effect on the other tissues examined. Fig. 1 shows that estradiol increased rGal mRNA levels 1500-fold in castrated male rats, similar to the increase seen in ovariectomized females. In comparison, high doses of testosterone (500 ,ug per 100 g of body weight daily for 7 days) elevated pituitary rGal mRNA levels in castrated male rats only 2-fold. This modest effect was likely caused by 17,B-estradiol converted from testosterone by tissue aromatase because similar treatment with dihydrotestosterone had no effect on rGal mRNA concentration. Localization of pituitary rGal gene expression by in situ hybridization with radiolabeled cRNA probes revealed rGal mRNA to be widely distributed within the anterior lobe. As seen in Fig. 2 (Fig. 1B) . This transplantable tumor is comprised of prolactin-and GH-secreting cells from the anterior pituitary (29, 30 The effect of estrogen on pituitary rGal mRNA concentration depends on both the dose of hormone administered and the duration of exposure (Fig. 3) . Fig. 3A shows that tissue peptide concentrations were maximally stimulated after implantation of a 5-mm silastic capsule containing a 1:1 mixture of 17p-estradiol and cholesterol filler, while mRNA concentrations increased linearly to a 4-fold higher dose of 17f3-estradiol. In other experiments (data not shown), estradiol administration of only 0.1 ,ug/100 g of body weight to ovariectomized female rats increased rGal mRNA >50-fold.
Treatment of male rats with 17j3-estradiol (10 ttg/100 g of body weight) increased concentrations of pituitary rGal mRNA 30-fold within 6 hr. With continued estrogen treatment, mRNA levels continued to rise and did not plateau even after 7 days. Similarly, 17,f-estradiol treatment stimulated the production of Gal-IR in the anterior pituitary. However, significant increases in Gal-IR were not seen until 24 hr after the initiation of 17,8-estradiol treatment. Further increases in Gal-IR lagged behind the induction of rGal mRNA by 1-2 days (Fig. 3B) .
To determine whether physiologic levels of circulating estrogens can affect rGal gene expression, we examined rGal mRNA levels in the pituitaries ofadult female rats at different times during the estrous cycle (Fig. 4) . During diestrus, the concentration of pituitary rGal mRNA was extremely low, approximating levels seen in the pituitaries of male rats. rGal mRNA increased steadily during proestrus and peaked during estrus. On the morning of estrus, rGal mRNA concentrations were 32-fold higher than those on diestrus.
Gal-IR was undetectable in plasma of normal male or ovariectomized female rats in our immunoassay (assay sensitivity, 10 pg/ml). However, after treatment of ovariectomized female rats with 17/3-estradiol benzoate (10 Iug/100 g of body weight), Gal-IR was detectable in plasma at concentrations of z30 pg/ml. Estrogen-stimulation of rGal tissue levels was evident only in the pituitary. Moreover, after 17l3- With this protocol, a dose of4-8 units generates a steady-state serum estrogen level approximating that found in adult female rats during proestrus (31) . (B) Male CD-1 rats were treated with daily s.c.
injections of 17,B-estradiol benzoate (10 ,ug/100 g of body weight) in sesame oil. Except for the 6-hr determination, the final estradiol dose was administered 24 hr before sacrifice. Anterior pituitaries were isolated as described and divided sagittally in the midline. RNA was isolated from one half-pituitary from each animal, and rGal mRNA was measured as described in the legend for Fig. 1 . Arbitrary units were standardized to a mean of 1.0/10 ,ug of total RNA for control animals. Gal-IR was measured in acetic acid extracts of the other half-pituitaries as described. Results are expressed as the mean ± SEM of determinations from five to eight animals. estradiol treatment, galanin mRNA and peptide levels in the pituitary were at least 100-fold higher than in any other tissue examined. It (34) . They observed induction of rGal mRNA in the pituitaries of these rats after estrogen treatment similar to the stimulation described here in normal rat pituitaries.
The stimulation of both galanin and prolactin gene expression by estrogen suggests that one of these peptides could regulate the expression of the gene encoding the other. Moreover, these peptides are produced within the same or proximal cells within the anterior pituitary. We have observed that MtTW15 tumor-bearing animals do not express pituitary galanin without estrogen treatment. Animals bearing these tumors have extremely high circulating levels of prolactin and GH (29, 30) ; it is therefore unlikely that prolactin or OH stimulates rGal production significantly. Several studies have shown that galanin administered to animals increases pituitary secretion of prolactin and GH (6) (7) (8) (9) (10) (11) ). Galanin appears to mediate these effects at the hypothalamic level, and recent studies showed no direct effect of galanin on cultured pituitary cells (6, 12, 13) . However, these studies used pGal and, therefore, do not exclude a direct effect of the homologous peptide on rat prolactin-and GH-producing cells. The demonstration of galanin production within the anterior pituitary raises the possibility that galanin acts in this tissue through a paracrine or autocrine mechanism.
Because galanin has previously been undetectable in blood and its distribution limited to neurons (2), the peptide has been thought to act primarily as a neurotransmitter. The detection of Gal-IR in the plasma after 17p-estradiol stimulation suggests that pituitary galanin has a distal target and, therefore, may be an additional anterior pituitary hormone.
The precise physiologic role of galanin is presently unknown. The demonstration of secreted galanin and the regulation of rGal gene expression by 17,8-estradiol suggest that galanin synthesized in the pituitary may mediate one or more of the effects of estrogen, either locally or at distal sites.
The sensitivity of its response to 17p8-estradiol would permit galanin to amplify the effects of subtle changes in the concentration of circulating estrogens. Whether galanin participates in the control of lactation or reproductive function, or in the feedback control of estrogen secretion itself awaits further study.
